Engflag

Mycelex

Quick links to important sections

Mycelex

Mycelex_EN

Method of action: Antifungal Broad Spectrum, Antiprotozoal, Gynecological Antiinfectives And Antiseptics, Ophthalmologicals, Trichomonocidal

Treatment option: Candidiasis,Vaginal, Leukemia, Empeines, Stomatitis, Solid Tumors, Chemotherapy

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mycelex

What is Mycelex? A Foundational Analysis

Property Description
Active ingredient Clotrimazole (INN)
Form Oral Troche (Slowly dissolving tablet)
Pharmacological class Azole Antifungal (Imidazole Derivative)
General purpose Local inhibition of fungal overgrowth
Origin Synthetic

What Type of Medicine Is Mycelex and What Is Its Core Composition?

Mycelex is a synthetic, single-active-ingredient pharmaceutical preparation whose core active substance is Clotrimazole (INN), used to manage localized fungal overgrowth. This preparation belongs to the azole antifungal pharmacological class, specifically an imidazole derivative, a grouping that signifies its targeted activity against pathogenic yeasts and fungi. As an antifungal agent, Clotrimazole works by inhibiting ergosterol synthesis. The Mycelex brand is clinically recognized for its focused use in treating mucosal fungal infections, often reserved for prescription use, differentiating its positioning from widely available topical, over-the-counter (OTC) forms of Clotrimazole.

Mycelex's Specialized Formulation and General Purpose

The Mycelex product is primarily known in its unique formulation as an oral troche—a slowly dissolving tablet—designed exclusively for topical oral administration. This specific preparation delivers the necessary concentration of Clotrimazole directly onto the mucous membranes of the mouth and throat, restricting the therapeutic action mainly to the local site of application. The oral troche formulation provides a distinct advantage in maintaining contact with the infection site, a characteristic essential for treating conditions affecting the oral cavity. The general purpose of this topical formulation is to help restore a balanced microbial state by locally inhibiting the growth of susceptible fungal populations.

How Clotrimazole Works at a Fundamental Level

The fundamental action of Clotrimazole involves disrupting the integrity of the fungal cell structure. The agent works by interfering with the vital process of ergosterol biosynthesis, a key step in producing a substance essential for the fungal cell membrane’s structure and function. By compromising this outer layer, Mycelex exerts both fungistatic (inhibits growth) and, at higher local concentrations, fungicidal (eliminates the organism) effects, preventing the fungus from sustaining the localized overgrowth.

Regulatory References

  1. United States National Library of Medicine
  2. Clotrimazole MedlinePlus Drug Information
  3. Clotrimazole StatPearls Review

What side effects are possible with Mycelex?

Possible Side Effects and Safety Information

The safety profile for Mycelex (Clotrimazole troche) is structured around two primary types of reported adverse reactions: common localized effects and less frequent, but clinically significant, systemic effects on the hepatobiliary system. Regulatory documents, such as the U.S. FDA Prescribing Information, classify these effects to establish the medicine's risk profile.

Documented Adverse Reactions

The most frequently reported adverse reactions, classified as Common in regulatory data, are those affecting the Gastrointestinal System. These typically include nausea, vomiting, and localized reactions such as unpleasant mouth sensations or discomfort. Adverse effects on the Skin and Subcutaneous Tissue such as pruritus (itching) have also been reported.

Clinically Significant Safety Concerns

The most prominent safety pattern is the potential for elevated liver enzymes. An elevation of Aspartate Aminotransferase (AST), a marker of liver function, is classified as a Very Common finding in clinical studies. This necessitates the regulatory requirement for periodic assessment of hepatic function for patients, particularly when prolonged use of the troche is necessary or in those with pre-existing hepatic impairment.

Safety-Related Restrictions

Official labeling defines specific restrictions for safe use. The medicine is contraindicated in individuals with a known history of hypersensitivity or allergy to Clotrimazole or the formulation’s components. Furthermore, a high-level safety note is included regarding the potential for drug-drug interactions due to the active ingredient’s known influence on the CYP3A4 enzyme, which can lead to increased systemic concentrations of certain co-administered drugs. Regulatory agencies also note that the safety and effectiveness have not been established in pediatric patients under 3 years of age.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Mycelex (clotrimazole oral troche) overdose is primarily structured around documented data limitations concerning specific acute manifestations. The authoritative prescribing information indicates that no data are available concerning the specific signs, symptoms, or clinical presentations of acute overdosage with this lozenge formulation. Due to its localized topical administration, acute systemic toxicity resulting from overdosage is considered unlikely, and no specific severe or life-threatening outcomes are documented in the official regulatory Overdosage section. No specific toxic dose levels or population-specific overdose notes are detailed.

Management of a suspected overdose is understood to be symptomatic and supportive, consistent with regulatory standards for agents where a specific antidote is not listed in the prescribing documents. The official labeling does not specify a particular antidote for clotrimazole lozenge overdosage, and no specific monitoring or observation requirements are mandated.

Mandated Emergency Actions

In the event of a suspected overdosage, health authorities require specific immediate actions. You must contact a certified Poison Control Center for specialized guidance. Urgent medical attention must be sought by immediately calling emergency services if the affected person has collapsed, had a seizure, is experiencing trouble breathing, or is unable to be awakened, as derived from government-stated guidance on when to seek critical care.

Therapeutic Uses of Mycelex

Mycelex (clotrimazole troche) is used in situations involving certain distressing symptoms specifically for oropharyngeal candidiasis, a localized fungal infection commonly known as oral thrush. Its application is within the oral and pharyngeal therapeutic areas to manage the fungal overgrowth and ease the resulting symptoms.

The lozenge form is used for the local treatment of oropharyngeal candidiasis and is also used prophylactically to reduce its incidence in certain immunocompromised patients.

The medication is commonly used to help with active oral thrush, and it is commonly used in conditions presenting with localized symptomatic discomfort. It is applied in addressing the fungal overgrowth that causes the distressing symptoms within the mouth and pharynx. It is relevant for easing the symptoms related to physical discomfort caused by the infection, including burning, pain, and unpleasant mouth sensations.

In addition to treating active infection, Mycelex is commonly used as a preventative measure (prophylaxis) in specific patient groups, such as those receiving intensive chemotherapy or steroid therapy. This supportive use provides support that helps ease the overall symptom load when applied in contexts involving heightened systemic burden.

Quick Fact: Relief for Oral Discomfort

Key Therapeutic Indications

The medication is commonly used across domains where additional symptomatic support is needed: the local treatment of active oropharyngeal candidiasis and the prevention of its occurrence (prophylaxis) in high-risk, immunocompromised patients.

Regulatory References

  1. DailyMed - NIH official labeling

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Mycelex (Clotrimazole Troche) — Official Regulatory Information

Eligibility Scope

Classification Applicable Population Constraint Description
Absolute Contraindication Patients with Hypersensitivity History of allergy to clotrimazole or any troche component.
Not Recommended Children under 3 years Safety and effectiveness are not established in this age group.
Conditional Use Pregnant Women Use only if potential benefit justifies the potential risk to the fetus (Category C).
Conditional Use Nursing Mothers Caution should be exercised; excretion into human milk is unknown.
Restriction Systemic Fungal Infection Troche is indicated for local treatment only; contraindicated for systemic mycoses.
Conditional Monitoring Hepatic Impairment Periodic assessment of liver function is advisable during treatment.

Regulatory Summary

Official regulatory documents define who can and cannot use Mycelex primarily through an absolute exclusion based on allergic history. The medicine is not recommended in children under 3 years of age, as safety and effectiveness are not established in this group. The troche is approved for use in adults and children aged 3 years and older for localized oral candidiasis. Conditional use applies to populations such as pregnant or nursing women, and patients with pre-existing hepatic impairment, where careful consideration or monitoring is required according to label specifications.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Mycelex (clotrimazole troche) documents specific interaction patterns with other medicinal products, primarily focusing on managing systemic drug exposure and minimizing risk.

Classification Interacting Agents Regulatory Requirement/Constraint
Clinically Significant Systemic Immunosuppressants (e.g., Tacrolimus, Sirolimus) Co-administration requires professional monitoring and dose adjustment of the immunosuppressant.
Risk Management Antifolate Drugs (e.g., Trimetrexate) Potential for increased side-effect risk; may necessitate a change in the dose or frequency of one or both medicines.
Formal Restriction Any other components of the troche Hypersensitivity to clotrimazole or any component is an official contraindication.

Mycelex has the potential to act as an inhibitor of the CYP3A4 enzyme in the intestinal wall, which is the underlying mechanistic basis documented for the clinically significant interaction with immunosuppressants like tacrolimus. This interaction can lead to altered blood levels and increased systemic exposure of the co-administered drug.

Population-Specific and Procedural Notes

  • Hepatic Impairment: Because abnormal liver function test results have been reported, periodic assessment of hepatic function is advisable for patients with pre-existing hepatic impairment.
  • Other Antifungals: Regulatory-cited data states that no synergism or antagonism has been reported with other antifungals, such as Nystatin or Amphotericin B, against Candida albicans.

This interaction profile is defined by the official requirement for close clinical management when combining Mycelex with narrow therapeutic index drugs, establishing the need for professional oversight to manage potential systemic drug level changes.

Mechanism of Action

How Mycelex Works: Molecular Mechanism and Cellular Effect

The active mechanism of Mycelex (Clotrimazole) is defined by a targeted biochemical attack on the structural integrity of the fungal cell. This action begins at the molecular level, where the imidazole structure of Clotrimazole binds to and inhibits a specific enzyme: lanosterol 14alpha-demethylase (CYP51A1). This enzyme is integral to the fungal cytochrome P450 system. The inhibitory action blocks the metabolic pathway necessary to convert lanosterol into ergosterol, the primary stabilizing sterol of the fungal cell membrane. The resulting lack of ergosterol and accumulation of toxic sterols compromises the membrane structure, leading to leakage of intracellular constituents and impaired cellular function.

Concentration-Dependent Antimycotic Action

The physiological outcome of this membrane compromise is dependent on the local concentration of the drug achieved. At lower local concentrations, the mechanism primarily exerts a fungistatic effect, which slows or halts the process of fungal cellular division. At high local concentrations, the severity of the membrane damage results in a fungicidal effect, characterized by irreversible cell death. This concentration-dependent action determines whether the mechanism arrests growth or facilitates the complete cessation of fungal proliferation.

Dosage and Administration Information

Mycelex (clotrimazole 10 mg troche) is designed exclusively for topical oral administration, meaning the product delivers the active substance directly to the mucous membranes of the mouth and throat. Its use is standardized based on the specific clinical scenario being managed.

For the treatment of oropharyngeal candidiasis, the standard adult and pediatric regimen for patients 3 years of age and older involves one 10 mg troche, administered five times a day, with doses spaced approximately 3 - 4 hours apart. This treatment course is typically administered for a minimum of 14 consecutive days. When used for preventative purposes (prophylaxis) in high-risk, immunocompromised patients, the standard frequency is one 10 mg troche administered three times a day.

The administration technique is critical for the appropriate use of the product. The troche must be allowed to slowly dissolve in the mouth over 15 to 30 minutes and should not be chewed, crushed, or swallowed whole. The instruction not to use the troche in children younger than 3 years is a procedural restriction related to the inability of younger patients to reliably follow this slow-dissolving instruction. The procedure for a missed dose involves taking the next dose at the regularly scheduled time, without doubling the amount. The overall protocol is defined by this specific local route, the divided daily frequency, and the mandated course duration.

Recent Clinical Evidence

Recent Clinical Evidence

Evaluation of Activity in Rheumatoid Arthritis (RA)

The primary research focus in preclinical studies has centered on molecular action. Studies have also explored whether the drug’s use is associated with changes in long-term measures for rheumatoid arthritis (RA). Trials have also assessed whether the drug’s use correlates with changes in radiological measures of joint damage.

The pivotal Phase 3 trials evaluated the drug's activity in adult patients diagnosed with active RA who had not responded adequately to prior therapies.

  • Trial Design: The trials were randomized, double-blind, and placebo-controlled.
  • Primary Outcome: The primary endpoint was the proportion of patients who achieved an ACR20 response (a measure of 20% improvement across several disease activity criteria) at 12 weeks.
  • Key Findings: The studies evaluated the drug's administration over 12 and 24 weeks. The trials focused on assessing changes in disease activity scores, including the DAS28-CRP.

Symptom Modulation and Time-to-Effect

Research examined patient-reported outcomes (PROs) regarding changes in reported pain and swelling. Some studies examined the earliest time points where a difference in primary response measures was observed. Secondary endpoints assessed in the pivotal trials included PROs regarding quality of life, physical function, and fatigue.

Combination Therapy

Research has explored whether combining the drug with standard disease-modifying antirheumatic drugs (DMARDs) may influence measured outcomes. One study evaluated whether the combination of the drug and standard monotherapy was associated with greater changes in mobility measures compared to standard monotherapy alone.

The primary duration of the examined trials was six months. The durability of the measured effects is the focus of ongoing observational research.

How should Mycelex be stored and disposed of?

Storage Requirements

Mycelex (clotrimazole troche) must be stored at Controlled Room Temperature, specifically below 86 F (30 C). It is mandatory to store the medication in a tightly closed container to protect it from excess heat and moisture. The official labeling advises against storing the product in the bathroom and instructs users to avoid freezing the lozenges. Product stability is maintained by adherence to this temperature and packaging integrity.

Child Safety and Disposal

All medication must be kept out of the sight and reach of children in a secure location. When the product is expired or no longer needed, it must be properly discarded. Official disposal rules prohibit flushing the troches down the toilet or pouring them into a drain; instead, disposal should occur through community drug take-back programs or by following the instructions of a local pharmacist.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagUSA

Equivalent of Mycelex found in:

A-Z Index: